The Neurofibromatosis Type 2 Gene Product, merlin, Reverses the F-Actin Cytoskeletal Defects in Primary Human Schwannoma Cells

REFERENCES

• Bianchi, A., T. Hara, V. Ramesh, J. Gao, A. Klein-Szanto, F. Morin, A. Menon, J. Trofatter, J. Gusella, et al. 1994. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat. Genet. 6: 185–192.
   PubMed Web of Science ®Google Scholar
• Bretscher, A., D. Chambers, R. Nguyen, and D. Reczek. 2000. ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Annu. Rev. Cell. Dev. Biol. 16: 113–143.
   PubMedGoogle Scholar
• Bruder, C. E., C. Hirvela, I. Tapia-Paez, I. Fransson, R. Segraves, G. Hamilton, Z. Z. Zhang, D. G. Evans, A. J. Wallace, et al. 2001. High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum. Mol. Genet. 10: 271–282.
   PubMedGoogle Scholar
• Chin, L., A. Tam, J. Pomerantz, M. Wong, J. Holash, N. Bardeesy, Q. Shen, R. O'Hagan, J. Pantginis, et al. 1999. Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468–472.
   PubMed Web of Science ®Google Scholar
• d'Ardenne, A. J., P. Kirkpatrick, and B. C. Sykes. 1984. Distribution of laminin, fibronectin, and interstitial collagen type III in soft tissue tumours. J. Clin. Pathol. 37: 895–904.
   PubMedGoogle Scholar
• den Bakker, M. A., P. H. Riegman, A. P. Suurmeijer, C. J. Vissers, M. Sainio, O. Carpen, and E. C. Zwarthoff. 2000. Evidence for a cytoskeleton attachment domain at the N terminus of the NF2 protein. J. Neurosci. Res. 62: 764–771.
   PubMedGoogle Scholar
• Erlandson, R. A., and J. M. Woodruff. 1982. Peripheral nerve sheath tumors: an electron microscopic study of 43 cases. Cancer 49: 273–287.
   PubMed Web of Science ®Google Scholar
• Evans, D. G., L. Trueman, A. Wallace, S. Collins, and T. Strachan. 1998. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J. Med. Genet. 35: 450–455.
   PubMedGoogle Scholar
• Giovannini, M., E. Robanus-Maandag, M. van der Valk, M. Niwa-Kawakita, V. Abramowski, L. Goutebroze, J. M. Woodruff, A. Berns, and G. Thomas. 2000. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 14: 1617–1630.
   Google Scholar
• Gonzalez-Agosti, C., L. Xu, D. Pinney, R. Beauchamp, W. Hobbs, J. Gusella, and V. Ramesh. 1996. The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene 13: 1239–1247.
   PubMed Web of Science ®Google Scholar
• Gronholm, M., M. Sainio, F. Zhao, L. Heiska, A. Vaheri, and O. Carpen. 1999. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J. Cell Sci. 112: 895–904.
   PubMedGoogle Scholar
• Gutmann, D. H., A. Aylsworth, J. C. Carey, B. Korf, J. Marks, R. E. Pyeritz, A. Rubenstein, and D. Viskochil. 1997. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278: 51–57.
   Google Scholar
• Gutmann, D. H., L. Sherman, L. Seftor, C. Haipek, K. Hoang Lu, and M. Hendrix. 1999. Increased expression of the NF2 tumor suppressor geneproduct, merlin, impairs cell motility, adhesion and spreading. Hum. Mol. Genet. 8: 267–275.
   PubMed Web of Science ®Google Scholar
• Gutmann, D. H., A. C. Hirbe, and C. A. Haipek. 2001. Functional analysis of neurofibromatosis 2 (NF2) missense mutations. Hum. Mol. Genet. 10: 1519–1529.
   PubMedGoogle Scholar
• Huang, L., E. Ichimaru, K. Pestonjamasp, X. Cui, H. Nakamura, G. Y. Lo, F. I. Lin, E. J. Luna, and H. Furthmayr. 1998. Merlin differs from moesin in binding to F-actin and in its intra- and intermolecular interactions. Biochem. Biophys. Res. Commun. 248: 548–553.
   PubMedGoogle Scholar
• Hung, G., R. Faudoa, X. Li, Z. Xeu, D. E. Brackmann, W. Hitselberg, E. Saleh, F. Lee, D. H. Gutmann, et al. 1999. Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients. Int. J. Oncol. 14: 409–415.
   PubMedGoogle Scholar
• Huynth, D. P., and S. M. Pulst. 1996. Neurofibromatosis 2 antisense oligodeoxynucleotides induce reversible inhibition of schwannomin synthesis and cell adhesion in STS26T and T98G cells. Oncogene 13: 73–84.
   PubMedGoogle Scholar
• Irving, R. M., T. Harada, D. A. Moffat, D. G. Hardy, J. L. Whittaker, J. H. Xuereb, and E. R. Maher. 1997. Somatic neurofibromatosis type 2 gene mutations and growth characteristics in vestibular schwannoma. Am. J. Otol. 18: 754–760.
   PubMedGoogle Scholar
• Jacoby, L. B., D. Jones, K. Davis, D. Kronn, M. P. Short, J. Gusella, and M. MacCollin. 1997. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am. J. Hum. Genet. 61: 1293–1302.
   PubMedGoogle Scholar
• Johnson, M. D., A. D. Glick, and B. W. Davis. 1988. Immunohistochemical evaluation of Leu-7, myelin basic-protein, S100-protein, glial-fibrillary acidic-protein, and LN3 immunoreactivity in nerve sheath tumors and sarcomas. Arch. Pathol. Lab. Med. 112: 155–160.
   PubMed Web of Science ®Google Scholar
• Kawahara, E., Y. Oda, A. Ooi, S. Katsuda, I. Nakanishi, and S. Umeda. 1988. Expression of glial fibrillary acidic protein (GFAP) in peripheral nerve sheath tumors. Am. J. Surg. Pathol. 12: 115–120.
   PubMed Web of Science ®Google Scholar
• Maeda, M., T. Matsui, M. Imamura, S. Tsukita, and S. Tsukita. 1999. Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with ezrin/radixin/moesin proteins. Oncogene 18: 4788–4797.
   PubMed Web of Science ®Google Scholar
• Marchionni, M. A., A. D. Goodearl, M. S. Chen, O. Bermingham-McDonogh, C. Kirk, M. Hendricks, F. Danehy, D. Misumi, J. Sudhalter, et al. 1993. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362: 312–318.
   PubMed Web of Science ®Google Scholar
• Meng, J. J., D. J. Lowrie, H. Sun, E. Dorsey, P. D. Pelton, A-M. Bashour, J. Groden, N. Ratner, and W. Ip. 2000. Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin. J. Neurosci. Res. 62: 491–502.
   PubMed Web of Science ®Google Scholar
• Merel, P., K. Haong-Xuan, M. Sanson, A. Moreau-Aubry, E. K. Bijlsma, C. Lazaro, J. P. Moisan, F. Resche, I. Nishisho, et al. 1995. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 13: 211–216.
   PubMed Web of Science ®Google Scholar
• Mettouchi, A., S. Klein, W. Guo, M. Lopez-Lago, E. Lemichez, J. Westwick, and F. Giancotti. 2001. Integrin-specific activation of Rac controls progression through the G1 phase of the cell cycle. Mol. Cell 8: 115–127.
   PubMed Web of Science ®Google Scholar
• Morrison, H., L. Sherman, J. Legg, F. Banine, C. Isacke, C. A. Haipek, D. H. Gutmann, H. Ponta, and P. Herrlich. 2001. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 15: 968–980.
   PubMed Web of Science ®Google Scholar
• Nagahara, H., A. M. Vocero-Akbani, E. L. Snyder, A. Ho, D. G. Latham, N. A. Lissy, M. Becker-Hapak, S. A. Ezhevsky, and S. F. Dowdy. 1998. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4: 1449–1452.
   PubMed Web of Science ®Google Scholar
• Nguyen, R., D. Reczek, and A. Bretscher. 2001. Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. J. Biol. Chem. 276: 7621–7629.
   PubMedGoogle Scholar
• Obremski, V. J., A. M. Hall, and C. Fernandez-Valle. 1998. Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells. J. Neurobiol. 37: 487–501.
   PubMedGoogle Scholar
• Parry, D. M., M. M. MacCollin, M. I. Kaiser-Kupfer, K. Pulaski, H. S. Nicholson, M. Bolesta, R. Eldridge, and J. F. Gusella. 1996. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am. J. Hum. Genet. 59: 529–539.
   PubMed Web of Science ®Google Scholar
• Pelton, P. D., T. A. Rizvi, L. Sherman, M. A. Marchionni, P. Wood, R. A. Friedman, and N. Ratner. 1998. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwann cells. Oncogene 17: 2195–2209.
   PubMed Web of Science ®Google Scholar
• Ridley, A. J., H. F. Paterson, C. L. Johnston, D. Diekmann, and A. Hall. 1992. The small GTP-binding protein Rac regulates growth factor-induced membrane ruffling. Cell 70: 401–410.
   PubMed Web of Science ®Google Scholar
• Roche, P. H., D. Figarella-Branger, L. Daniel, N. Bianco, W. Pellet, and J. F. Pellissier. 1997. Expression of cell adhesion molecules in normal nerves, chronic axonal neuropathies and Schwann cell tumors. J. Neurol. Sci. 151: 127–133.
   PubMedGoogle Scholar
• Rosenbaum, C., L. Kluwe, V. F. Mautner, R. E. Friedrich, H. W. Muller, and C. O. Hanemann. 1998. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol. Dis. 5: 55–64.
   PubMedGoogle Scholar
• Rouleau, G. A., P. Merel, M. Lutchman, M. Sanson, J. Zucman, C. Marineau, K. Hoang-Xuan, S. Demczuk, C. Desmaze, B. Plougastel, et al. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363: 515–521.
   Google Scholar
• Ruttledge, M. H., A. A. Andermann, C. M. Phelan, J. O. Claudio, F. Y. Han, N. Chretien, S. Rangaratnam, M. MacCollin, P. Short, et al. 1996. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am. J. Hum. Genet. 59: 331–342.
   PubMed Web of Science ®Google Scholar
• Sainio, M., F. Zhao, L. Heiska, O. Turunen, M. den Bakker, E. Zwarthoff, M. Lutchman, G. A. Rouleau, J. Jaaskelainen, et al. 1997. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J. Cell Sci. 110: 2249–2260.
   PubMedGoogle Scholar
• Scherer, S. S., and D. H. Gutmann. 1996. Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells. J. Neurosci. Res. 46: 595–605.
   PubMedGoogle Scholar
• Schwarze, S. R., K. Hruska, and S. F. Dowdy. 2000. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol. 10: 290–295.
   PubMed Web of Science ®Google Scholar
• Shaw, R. J., M. Henry, F. Solomon, and T. Jacks. 1998. RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. Mol. Biol. Cell 9: 403–419.
   PubMedGoogle Scholar
• Shaw, R. J., A. I. McClatchey, and T. Jacks. 1998. Localization and functional domains of the neurofibromatosis type II tumor suppressor, merlin. Cell Growth Differ. 9: 287–296.
   PubMedGoogle Scholar
• Shaw, R. J., J. G. Paez, M. Curto, A. Yaktine, W. M. Pruit, I. Saotome, J. P. O'Brian, V. Gupta, N. Ratner, C. J. Der T. Jacks, and A. I. McClatchey. 2001. The NF2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell 1: 63–72.
   PubMed Web of Science ®Google Scholar
• Sherman, L., H-M. Xu, R. T. Geist, S. Saporito-Irwin, N. Howells, P. Ponta, P. Herrlich, and D. Gutmann. 1997. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15: 2505–2509.
   PubMed Web of Science ®Google Scholar
• Stemmer-Rachamimov, A. O., L. Xu, C. Gonzalez-Agosti, J. A. Burwick, D. Pinney, R. Beauchamp, L. B. Jacoby, J. F. Gusella, V. Ramesh, et al. 1997. Universal absence of merlin, but not other ERM family members, in schwannomas. Am. J. Pathol. 151: 1649–1654.
   PubMed Web of Science ®Google Scholar
• Stokowski, R. P., and D. R. Cox. 2000. Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations. Am. J. Hum. Genet. 66: 873–891.
   PubMedGoogle Scholar
• Trofatter, J. A., M. M. MacCollin, J. L. Rutter, J. R. Murrell, M. P. Duyao, D. M. Parry, R. Eldridge, N. Kley, A. G. Menon, K. Pulaski, et al. 1993. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72: 791–800.
   PubMed Web of Science ®Google Scholar
• Xu, H-M., and D. H. Gutmann. 1998. Merlin differentially associates with the microtubule and actin cytoskeleton. J. Neurosci. Res. 51: 403–415.
   PubMed Web of Science ®Google Scholar